A Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Trial to Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects without Diabetes Mellitus
CONDITION: Metabolic and Endocrine
GENDER: All
AGE GROUP: 18 to 75 years
TRIAL STATUS: Active, not recruiting
A Phase 3, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS‑CoV‑2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine with Matrix-M™ Adjuvant and a …
CONDITION: Other
GENDER: All
AGE GROUP: 60 and above
TRIAL STATUS: Active, not recruiting
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
CONDITION: Other
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
A Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate a Switch to an Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care
CONDITION: Other
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
CONDITION: Skin
GENDER: All
AGE GROUP: 18 to 75 years
TRIAL STATUS: Active, not recruiting
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment …
CONDITION: Other
GENDER: All
AGE GROUP: 18 to 65 years
TRIAL STATUS: Active, not recruiting
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This study is being done to see how well a new HIV treatment works compared to current standard treatment. Researchers are testing a single tablet that combines bictegravir (BIC) and …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This study is for people living with HIV whose treatment is already keeping the virus under control. Researchers are testing whether switching to new medicines, bictegravir and lenacapavir (together in …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This study is testing whether people with HIV whose virus is already well controlled can safely switch from their current daily HIV medicines to a new once-a-week pill (islatravir/lenacapavir).
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This is a large final-stage (Phase 3) clinical trial testing whether people living with HIV, who already have their virus under control on the standard daily HIV pill (Biktarvy® – …
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
Australian researchers are testing a new treatment for non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD). A new medication is to be taken orally 3 times …
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
SLT for Vascular Dementia Vascular dementia (VaD) is the second major cause of dementia accounting for 15-20 per cent of all dementia cases. VaD is an acquired cognitive impairment due …
CONDITION: Neurological
GENDER: Both males and females
AGE GROUP: 40 and above
TRIAL STATUS: Active, not recruiting
Youth aged 12 to 17 with a history of eczema (atopic dermatitis) for at least one year, may qualify to participate in this study. Adolescents must have moderate to severe …
CONDITION: Skin
GENDER: Both males and females
AGE GROUP: 12 to 17 years
TRIAL STATUS: Active, not recruiting
The RESTORE clinical trial is a large scale research study in Australia exploring back pain treatments. We are trying to measure how effective existing treatments are for people with persistent …
CONDITION: Musculoskeletal
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
Title: A non-interventional, prospective 12 months study to characterize the REAL-life effectiveness and treatment patterns of Secukinumab and current standard of care in patient with chronic plaque psoriAsis eligible for …
CONDITION: Skin
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting